Sector Gamma AS Has $15.69 Million Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Sector Gamma AS trimmed its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 29.1% in the first quarter, HoldingsChannel.com reports. The institutional investor owned 140,000 shares of the biopharmaceutical company’s stock after selling 57,500 shares during the quarter. Gilead Sciences comprises about 5.0% of Sector Gamma AS’s portfolio, making the stock its 7th biggest holding. Sector Gamma AS’s holdings in Gilead Sciences were worth $15,687,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in GILD. Smallwood Wealth Investment Management LLC bought a new position in Gilead Sciences in the 1st quarter worth approximately $25,000. Goodman Advisory Group LLC bought a new position in Gilead Sciences during the 1st quarter valued at $29,000. Core Alternative Capital boosted its stake in Gilead Sciences by 370.8% during the 1st quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company’s stock valued at $34,000 after purchasing an additional 241 shares in the last quarter. IMA Advisory Services Inc. bought a new position in Gilead Sciences during the 1st quarter valued at $39,000. Finally, Financial Network Wealth Advisors LLC boosted its stake in Gilead Sciences by 538.6% during the 1st quarter. Financial Network Wealth Advisors LLC now owns 364 shares of the biopharmaceutical company’s stock valued at $41,000 after purchasing an additional 307 shares in the last quarter. 83.67% of the stock is owned by institutional investors.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction dated Tuesday, July 15th. The stock was sold at an average price of $111.03, for a total value of $277,575.00. Following the completion of the sale, the chief financial officer owned 162,610 shares of the company’s stock, valued at $18,054,588.30. The trade was a 1.51% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Daniel Patrick O’day sold 10,000 shares of the business’s stock in a transaction dated Monday, July 28th. The stock was sold at an average price of $113.94, for a total value of $1,139,400.00. Following the completion of the sale, the chief executive officer directly owned 605,725 shares of the company’s stock, valued at $69,016,306.50. This represents a 1.62% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 79,500 shares of company stock worth $8,734,625 in the last ninety days. Company insiders own 0.27% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. Morgan Stanley increased their price target on Gilead Sciences from $130.00 to $135.00 and gave the company an “overweight” rating in a research note on Friday, April 25th. Cantor Fitzgerald assumed coverage on Gilead Sciences in a research note on Tuesday, April 22nd. They set an “overweight” rating and a $125.00 price target for the company. Needham & Company LLC raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $133.00 price target for the company in a research note on Friday, July 25th. Truist Financial raised Gilead Sciences from a “hold” rating to a “buy” rating and raised their price objective for the stock from $108.00 to $127.00 in a research note on Friday, August 8th. Finally, UBS Group raised their price objective on Gilead Sciences from $108.00 to $112.00 and gave the stock a “neutral” rating in a research note on Friday, August 8th. Seven investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $114.82.

Gilead Sciences Price Performance

GILD opened at $119.02 on Friday. The stock has a market cap of $147.68 billion, a price-to-earnings ratio of 23.71, a PEG ratio of 0.74 and a beta of 0.33. Gilead Sciences, Inc. has a 1 year low of $72.89 and a 1 year high of $121.83. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13. The stock has a fifty day moving average price of $111.76 and a 200 day moving average price of $108.16.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.96 by $0.05. The firm had revenue of $7.08 billion during the quarter, compared to analysts’ expectations of $6.95 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%. The business’s revenue for the quarter was up 1.4% on a year-over-year basis. During the same quarter last year, the firm earned $2.01 earnings per share. Analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, September 29th. Investors of record on Monday, September 15th will be given a dividend of $0.79 per share. The ex-dividend date of this dividend is Monday, September 15th. This represents a $3.16 dividend on an annualized basis and a yield of 2.7%. Gilead Sciences’s dividend payout ratio (DPR) is presently 62.95%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.